Observational studyPloS one2026
Admission interleukin-6 as a time-limited, etiology-dependent prognostic signal in hospitalized cirrhosis - A frequentist and Bayesian cohort study.
Observational study in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesInterleukin-6 is a proximal inflammatory cytokine implicated in cirrhosis decompensation, yet its incremental prognostic value over established severity scores remains unclear.
methodsIn this prospective, purely observational study (April 2022 to October 2023), 489 consecutive patients hospitalized with cirrhosis at a tertiary hepatology center were enrolled, and serum interleukin-6 was measured at admission.
resultsMedian interleukin-6 was 23.8 pg/mL, in-hospital mortality was 9.0%, and overall mortality was 70.6%. Interleukin-6 independently predicted in-hospital mortality after adjustment for age, sex, and disease severity (adjusted odds ratio 1.34, 95% confidence interval 1.08-1.67), supported by Bayesian analysis (posterior probability 99.6%). Adding interleukin-6 to conventional severity scores modestly but significantly improved discrimination for in-hospital mortality, with the combined organ failure score plus interleukin-6 model achieving the highest area under the curve (0.802). The prognostic impact of interleukin-6 was substantially stronger in alcohol-associated liver disease compared with metabolic dysfunction-associated steatotic liver disease. Infection mediated 17.3% of the interleukin-6-mortality association. In sub-cohort analyses, the etiology-specific effect persisted after adjustment for infection and after exclusion of severe alcohol-associated hepatitis; infection mediated 23% of the interleukin-6-mortality association in alcohol-associated liver disease but 2% in metabolic dysfunction-associated steatotic liver disease, and the incremental value of interleukin-6 over MELD-3.0 was confined to alcohol-associated disease and to infected patients. MELD-3.0 remained the dominant prognostic determinant, and interleukin-6's independent prognostic signal attenuated for longer-term outcomes.
conclusionsAdmission interleukin-6 did not outperform established severity scores but provided modest, statistically significant incremental discrimination that was confined to the in-hospital window and concentrated in alcohol-associated disease. These findings do not support routine interleukin-6 measurement in unselected admissions but identify alcohol-associated cirrhosis, particularly with infection or intermediate MELD-3.0 scores, as the setting in which interleukin-6-informed risk stratification merits prospective validation and economic evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.